Curious about the latest breakthroughs in oncology treatment? Prepare to have your perspective shifted and hopefully a few laughs too, as we dissect the most compelling research and clinical insights with our expert hosts, Professor Craig Underhill, Dr. Kate Clarke, and Professor Christopher Jackson.
Today’s episode covers an eclectic mix of papers from many different specialities. Craig tackles ASCO non-small cell lung cancer recommendations, sarcomas in Brazil and cardiovascular risks in cancer patients.
Kate dives into endometrial cancer, the HIMALAYA study and CAR-T.
CJ looks at colon cancer, pancreatic cancer and pain management.
And a shout-out to our Series 1 hosts Professor Eva Segelov and Professor Hans Prenen who both have papers in today’s episode!
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode, a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
We hope you enjoy listening and find this a valuable and entertaining resource.
PAPERS:
CJ:
Gallois, C., et al., Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. JCO 42, 2295-2305(2024). Access online here.
Kate:
Powell MA, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024 Jun 10:S0923-7534(24)00721-X. doi: 10.1016/j.annonc.2024.05.546. Epub ahead of print. PMID: 38866180. Access online here.
QUICKBITES:
Craig:
- Daly ME, et al. Management of Stage III NSCLC Guideline Expert Panel. Management of Stage III Non-Small Cell Lung Cancer: ASCO Rapid Recommendation Update. J Clin Oncol. 2024 Jul 23:JCO2401324. doi: 10.1200/JCO-24-01324. Epub ahead of print. PMID: 39042842. Access online here.
- Blackford AL, et al. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. JAMA Oncol. 2024 Jul 3:e241930. doi: 10.1001/jamaoncol.2024.1930. Epub ahead of print. PMID: 38959011; PMCID: PMC11223057. Access online here.
- Carlos Diego H. Lopes et al.Discordance Between the Initial Diagnosis of Sarcomas and Subsequent Histopathological Revision and Molecular Analyses in a Sarcoma Reference Center in Brazil. JCO Glob Oncol 10, e2300431(2024). Access online here.
- Tan S, et al. Cardiovascular Risk in Cancer Patients Treated with Immune Checkpoint Inhibitors: Challenges and Future Directions. Eur J Prev Cardiol. 2024 Jun 13:zwae204. doi: 10.1093/eurjpc/zwae204. Epub ahead of print. PMID: 38870247. Access online here.
Kate:
- Sangro B, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. PMID: 38382875. Access online here.
- Weinkove, R., et al. 890 A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE). ASH Annual Scientific Meeting Abstract: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B Cell Malignancies. Access online here.
CJ:
- Yaacov R Lawrence, Y, R., et al. Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial. The Lancet Oncology. July 16, 2024. Access online here.
- Laethem, J-L V,. et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study. The Lancet Oncology. June 01, 2024. Access online here.
HOSTS:
Craig Underhill
Professor Craig Underhill
Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
You can find Craig on X/Twitter here: @CraigUnderhill
Kate Clarke
Dr. Kate Clarke
Dr Kate Clarke (MBChB (Otago), FRACP) is a proud New Zealander with a real love for beautiful Aotearoa. Dr Clarke continues to work at being Tangata Tiriti. Much of her research and patient advocacy has an equity focus. Dr Clarke is grateful to her patients, students, whanau and colleagues for the knowledge and awhi they share. Ehara taku toa, he takitahi, he toa takitini.
Dr Clarke completed her medical training in Otago, Wellington and London. She has a holistic approach and is passionate about patient-centred care, and believes patients can and should play an active role in their healthcare. Her clinical experience covers a broad range of solid tumour malignancies with special clinical interest in colorectal cancer, upper gastrointestinal cancers and breast cancer.
Chris ‘CJ’ Jackson
Professor Christopher Jackson
Chris Jackson is Professor of Medical Oncology at the University of Otago, Dunedin, and a medical oncologist at Dunedin Hospital and Mercy Cancer Care. He specialises in GI cancers and melanoma, teaches medical students and specialists-in-training, and is heavily involved in both national and international cancer policy, leadership and research.
He was previously the medical director of the Cancer Society of NZ, and his advocacy led to the funding of new cancer drugs, to the development of a new national cancer plan, and to the birth of the national cancer agency Te Aho o Te Kahu. He currently chairs the agency’s clinical committee and serves on the advisory board. In addition, he is on the programme board of the International Cancer Benchmarking Project, and is a founding member of the Common Sense Oncology movement.
Chris is a self-confessed Radiohead tragic, and recent convert to Crossfit (even though you didn’t ask).
Connect with CJ on X/Twitter: @drkiwicj
PRODUCER:
Rachael Babin
Rachael Babin is Host of The Oncology Podcast, Editor-in-Chief of The Oncology Newsletter, and Publisher of Oncology News Australia and The Oncology Network.
With a background in oncology communications and academic publishing, Rachael is happiest sitting behind the mic chatting to interesting people about the impact their work makes in oncology.
Connect on Twitter: @OncologyNewsAus
